BMI1 and endometrial cancer: These findings suggest that drugs based on negative regulation of BMI‐1 protein expression such as PTC‐596 which is currently in clinical development and is used in patients with advanced solid tumours (NCT02404480), may be not suitable for advanced endometrial cancer.